Recently, the Class 1 innovative drug Crisugabalin Besilate Capsules (trade name: 思美宁) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for adult patients with diabetic peripheral neuropathic pain.

Crisugabalin Besilate is a structural derivative of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). The marketing of this drug provides new treatment options for adult patients with diabetic peripheral neuropathic pain.